Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-01-13 Sale | 2026-01-15 5:22 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 111,227 | $0.55551 | $61,787 | 2,198,642 (Indirect) | View |
| 2026-01-08 Sale | 2026-01-12 5:09 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 91,374 | $0.58587 | $53,533 | 2,309,869 (Indirect) | View |
| 2026-01-05 Sale | 2026-01-07 5:12 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 71,054 | $0.64574 | $45,882 | 2,401,243 (Indirect) | View |
| 2025-12-30 Sale | 2026-01-02 5:32 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 78,377 | $0.61792 | $48,431 | 2,472,297 (Indirect) | View |
| 2025-12-22 Sale | 2025-12-29 5:27 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 291,283 | $0.63588 | $185,221 | 2,550,674 (Indirect) | View |
| 2025-12-15 Sale | 2025-12-17 6:28 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 48,171 | $1.0785 | $51,951 | 2,841,957 (Indirect) | View |
| 2025-12-10 Sale | 2025-12-12 5:32 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 82,971 | $1.0677 | $88,587 | 2,890,128 (Indirect) | View |
| 2025-12-05 Sale | 2025-12-09 5:07 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 95,179 | $0.99588 | $94,787 | 2,973,099 (Indirect) | View |
| 2025-12-02 Sale | 2025-12-04 6:20 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 128,185 | $0.91761 | $117,623 | 3,068,278 (Indirect) | View |
| 2025-12-02 Sale | 2025-12-04 6:19 pm | Werewolf Therapeutics Inc. | HOWL | MPM BioVentures 2014 L.P. MPM BioVentures 2014 (B) L.P. MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM Asset Management Investors BV2014 LLC Former 10% Owner | 199,732 | $0.91761 | $183,275 | 4,784,111 (Indirect) | View |
| 2025-12-02 Sale | 2025-12-04 6:18 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM BioImpact LLC MPM Oncology Innovations Fund GP LLC MPM ASSET MANAGEMENT LLC Former 10% Owner | 199,732 | $0.91761 | $183,275 | 4,784,111 (Indirect) | View |
| 2025-11-26 Sale | 2025-12-01 6:13 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 91,088 | $0.96426 | $87,833 | 3,196,463 (Indirect) | View |
| 2025-11-26 Sale | 2025-12-01 6:12 pm | Werewolf Therapeutics Inc. | HOWL | MPM BioVentures 2014 L.P. MPM BioVentures 2014 (B) L.P. MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM Asset Management Investors BV2014 LLC 10% Owner | 141,927 | $0.96426 | $136,855 | 4,983,843 (Indirect) | View |
| 2025-11-26 Sale | 2025-12-01 6:11 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM BioImpact LLC MPM Oncology Innovations Fund GP LLC MPM ASSET MANAGEMENT LLC 10% Owner | 141,927 | $0.96426 | $136,855 | 4,983,843 (Indirect) | View |
| 2025-11-21 Sale | 2025-11-25 6:05 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 125,576 | $0.91764 | $115,234 | 3,287,551 (Indirect) | View |
| 2025-11-21 Sale | 2025-11-25 6:04 pm | Werewolf Therapeutics Inc. | HOWL | MPM BioVentures 2014 L.P. MPM BioVentures 2014 (B) L.P. MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM Asset Management Investors BV2014 LLC 10% Owner | 195,666 | $0.91764 | $179,551 | 5,125,770 (Indirect) | View |
| 2025-11-21 Sale | 2025-11-25 6:03 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM BioImpact LLC MPM Oncology Innovations Fund GP LLC MPM ASSET MANAGEMENT LLC 10% Owner | 195,666 | $0.91764 | $179,551 | 5,125,770 (Indirect) | View |
| 2025-11-18 Sale | 2025-11-20 5:52 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 102,753 | $0.92386 | $94,930 | 3,413,127 (Indirect) | View |
| 2025-11-18 Sale | 2025-11-20 5:51 pm | Werewolf Therapeutics Inc. | HOWL | MPM BioVentures 2014 L.P. MPM BioVentures 2014 (B) L.P. MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM Asset Management Investors BV2014 LLC 10% Owner | 160,103 | $0.92386 | $147,913 | 5,321,436 (Indirect) | View |
| 2025-11-18 Sale | 2025-11-20 5:50 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM BioImpact LLC MPM Oncology Innovations Fund GP LLC MPM ASSET MANAGEMENT LLC 10% Owner | 160,103 | $0.92386 | $147,913 | 5,321,436 (Indirect) | View |
| 2025-11-13 Sale | 2025-11-17 7:23 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 134,553 | $0.95713 | $128,785 | 3,515,880 (Indirect) | View |
| 2025-11-13 Sale | 2025-11-17 7:22 pm | Werewolf Therapeutics Inc. | HOWL | MPM BioVentures 2014 L.P. MPM BioVentures 2014 (B) L.P. MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM Asset Management Investors BV2014 LLC 10% Owner | 209,652 | $0.95713 | $200,665 | 5,481,539 (Indirect) | View |
| 2025-11-13 Sale | 2025-11-17 7:20 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM BioImpact LLC MPM Oncology Innovations Fund GP LLC MPM ASSET MANAGEMENT LLC 10% Owner | 209,652 | $0.95713 | $200,665 | 5,481,539 (Indirect) | View |
| 2025-11-07 Sale | 2025-11-12 7:49 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 137,041 | $1.13 | $154,850 | 3,650,433 (Indirect) | View |
| 2025-11-07 Sale | 2025-11-12 7:32 pm | Werewolf Therapeutics Inc. | HOWL | MPM BioVentures 2014 L.P. MPM BioVentures 2014 (B) L.P. MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM Asset Management Investors BV2014 LLC 10% Owner | 213,529 | $1.13 | $241,278 | 5,691,191 (Indirect) | View |
| 2025-11-07 Sale | 2025-11-12 7:31 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM BioImpact LLC MPM Oncology Innovations Fund GP LLC MPM ASSET MANAGEMENT LLC 10% Owner | 213,529 | $1.13 | $241,278 | 5,691,191 (Indirect) | View |
| 2025-11-04 Sale | 2025-11-06 7:43 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 155,885 | $1.2178 | $189,830 | 3,787,474 (Indirect) | View |
| 2025-11-04 Sale | 2025-11-06 7:41 pm | Werewolf Therapeutics Inc. | HOWL | MPM BioVentures 2014 L.P. MPM BioVentures 2014 (B) L.P. MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM Asset Management Investors BV2014 LLC 10% Owner | 242,890 | $1.2178 | $295,781 | 5,904,720 (Indirect) | View |
| 2025-11-04 Sale | 2025-11-06 7:40 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM BioImpact LLC MPM Oncology Innovations Fund GP LLC MPM ASSET MANAGEMENT LLC 10% Owner | 242,890 | $1.2178 | $295,781 | 5,904,720 (Indirect) | View |
| 2025-10-30 Sale | 2025-11-03 7:11 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 189,356 | $1.3274 | $251,349 | 3,943,359 (Indirect) | View |
| 2025-10-30 Sale | 2025-11-03 7:08 pm | Werewolf Therapeutics Inc. | HOWL | MPM BioVentures 2014 L.P. MPM BioVentures 2014 (B) L.P. MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM Asset Management Investors BV2014 LLC 10% Owner | 295,043 | $1.3274 | $391,636 | 6,147,610 (Indirect) | View |
| 2025-10-30 Sale | 2025-11-03 7:07 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM BioImpact LLC MPM Oncology Innovations Fund GP LLC MPM ASSET MANAGEMENT LLC 10% Owner | 295,043 | $1.3274 | $391,636 | 6,147,610 (Indirect) | View |
| 2025-10-27 Sale | 2025-10-29 7:22 pm | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 177,145 | $1.6173 | $286,497 | 4,132,715 (Indirect) | View |
| 2025-10-27 Sale | 2025-10-29 7:21 pm | Werewolf Therapeutics Inc. | HOWL | MPM BioVentures 2014 L.P. MPM BioVentures 2014 (B) L.P. MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM Asset Management Investors BV2014 LLC 10% Owner | 276,017 | $1.6173 | $446,403 | 6,442,653 (Indirect) | View |
| 2025-10-27 Sale | 2025-10-29 7:21 pm | Werewolf Therapeutics Inc. | HOWL | GADICKE ANSBERT MPM ONCOLOGY INNOVATIONS FUND LP UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. MPM BioImpact LLC MPM Oncology Innovations Fund GP LLC MPM ASSET MANAGEMENT LLC 10% Owner | 276,017 | $1.6173 | $446,403 | 6,442,653 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-06-12 Option Award | 2025-06-13 4:10 pm | N/A 2035-06-11 | Werewolf Therapeutics Inc. | HOWL | Lazarus Alon Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2025-06-12 Option Award | 2025-06-13 4:10 pm | N/A 2035-06-11 | Werewolf Therapeutics Inc. | HOWL | Morrison Briggs Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2025-06-12 Option Award | 2025-06-13 4:10 pm | N/A 2035-06-11 | Werewolf Therapeutics Inc. | HOWL | Chatterjee Meeta Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2025-06-12 Option Award | 2025-06-13 4:10 pm | N/A 2035-06-11 | Werewolf Therapeutics Inc. | HOWL | EVNIN LUKE Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2025-06-12 Option Award | 2025-06-13 4:10 pm | N/A 2035-06-11 | Werewolf Therapeutics Inc. | HOWL | Sherman Michael A. Director | 27,000 | $0 | 27,000 (Direct) | View |